WO2003011852A1 - Neue modifikationen des trometamolsalzes der r-thioctsäure sowie verfahren zu ihrer herstellung - Google Patents
Neue modifikationen des trometamolsalzes der r-thioctsäure sowie verfahren zu ihrer herstellung Download PDFInfo
- Publication number
- WO2003011852A1 WO2003011852A1 PCT/EP2002/007310 EP0207310W WO03011852A1 WO 2003011852 A1 WO2003011852 A1 WO 2003011852A1 EP 0207310 W EP0207310 W EP 0207310W WO 03011852 A1 WO03011852 A1 WO 03011852A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modification
- preparation
- mixtures
- addition
- straight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- the invention relates to new modifications of the trometamol seed of R-thioctic acid of the formula I,
- This compound is, for example, anti-inflammatory and cytoprotective (EP 427247) and is used for the treatment of diabetes mellitus and insulin resistance (DE 4,343,593) as well as for glucose metabolism disorders of the CNS (DE 4,343,592) and as an appetite suppressant (DE 19.818.563) used and can therefore be used in pharmaceutical preparations (EP 702953).
- the requirements for an active ingredient with regard to the physicochemical properties relevant for galenical processability and bioavailability are determined both by the type and the manufacturing technology of the respective pharmaceutical preparation.
- the physicochemical properties significantly influence the galenic processability and bioavailability.
- the invention is therefore based on the object of providing compound I in various modifications and mixtures thereof in accordance with the pharmaceutical requirements.
- the two modifications have different physicochemical properties.
- the characteristic X-ray powder diffractograms are used.
- the modifications also differ in their DSC curves (Differential Scanning Calorimetry), by the typical crystal shapes, the different solubilities or dissolution rates and the different flowability.
- Solvents such as lower alcohols, octanol and acetone and their
- R-thioctic acid polymerizes easily and tends to react in this way, especially in polar media.
- modifications A and B of the compound I and their mixtures of any composition can be obtained either by salt formation of R-thioctic acid with trometamol in suitable polar solvents such as, for example, lower alcohols as well as by modification conversion under special reaction conditions.
- nucleophilic compounds such as e.g. Sodium sulfite or 6,8-dimercaptooctanoic acid, in the salt formation with R-thioctic acid as the main product produced according to synthesis route a, the modification B.
- modifications can also be made by modification conversion, whereby a complete or partial conversion from A to B and from B to A can take place.
- a melt of modification A preferably about 10 to 40 min at about 115-130 ° C, in particular 15 to 25 min at about 115-120 ° C, and crystallization by Cooling.
- modifications A and B and their mixtures can be processed in a conventional manner with suitable carriers and / or auxiliaries to give pharmaceutical preparations.
- suitable carriers and / or auxiliaries to give pharmaceutical preparations.
- Preferred forms of use are tablets and capsules.
- Diacel filter aid
- Example 6 25.8 g (0.125 mol) of R-thioctic acid (prepared by method b) were dissolved in 375 ml of ethanol (anhydrous). Subsequently, 15.13 g (0.125 mol) of trometamol were introduced and the mixture was heated with stirring at 50-55 ° C. until dissolved.
- Diacel 1 g was stirred at 53-55 ° C for 20 min, suction filtered and the solution slowly cooled.
- Example 24 10 g of I, modification A, were dissolved in 30 ml of ethanol (96%) at 55 ° C. The mixture was then concentrated on a rotary evaporator to a maximum bath temperature of 100 ° C., finally under vacuum. The oil crystallized on cooling: mixture (approx. 1: 1) of modifications A and B, yield quantitative.
- R-thioctic acid prepared by process b
- 100 g of R-thioctic acid were dissolved in a mixture consisting of 760 ml of cyclohexane and 40 ml of water-saturated ethyl acetate (water content: 3.2%) at 40-42 ° C.
- the product was filtered with suction, slowly cooled to -5 ° C., stirred at this temperature for 1 h, suction filtered, washed with cyclohexane and dried at 30 ° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20020743253 EP1417199A1 (de) | 2001-07-31 | 2002-07-02 | Neue modifikationen des trometamolsalzes der r-thioctsäure sowie verfahren zu ihrer herstellung |
CA2451979A CA2451979C (en) | 2001-07-31 | 2002-07-02 | Novel modifications of the trometamol salt of r-thioctic acid and method for producing the same |
JP2003517044A JP2005506969A (ja) | 2001-07-31 | 2002-07-02 | R−チオクト酸のトロメタモル塩の新規変態およびその製法 |
KR1020047001501A KR100913684B1 (ko) | 2001-07-31 | 2002-07-02 | R-티옥트산의 트로메타몰 염의 신규한 결정체, 이의 제조방법 및 이를 포함하는 약제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10137381A DE10137381A1 (de) | 2001-07-31 | 2001-07-31 | Neue Modifikationen des Trometamolsalzes der R-Thioctsäure sowie Verfahren zu ihrer Herstellung |
DE10137381.3 | 2001-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003011852A1 true WO2003011852A1 (de) | 2003-02-13 |
Family
ID=7693786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/007310 WO2003011852A1 (de) | 2001-07-31 | 2002-07-02 | Neue modifikationen des trometamolsalzes der r-thioctsäure sowie verfahren zu ihrer herstellung |
Country Status (9)
Country | Link |
---|---|
US (3) | US6844449B2 (de) |
EP (1) | EP1417199A1 (de) |
JP (1) | JP2005506969A (de) |
KR (1) | KR100913684B1 (de) |
CN (2) | CN100410248C (de) |
CA (1) | CA2451979C (de) |
DE (1) | DE10137381A1 (de) |
HK (1) | HK1098743A1 (de) |
WO (1) | WO2003011852A1 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100935554B1 (ko) | 2009-06-24 | 2010-01-07 | 주식회사 셀트리온제약 | 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물 |
CN113197845A (zh) * | 2020-12-16 | 2021-08-03 | 南京海融制药有限公司 | 一种硫辛酸氨丁三醇注射液及其制备方法 |
CN113200959A (zh) * | 2020-12-16 | 2021-08-03 | 南京海融制药有限公司 | 一种硫辛酸氨丁三醇盐晶型及其制备方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10201464B4 (de) * | 2002-01-16 | 2005-06-16 | Viatris Gmbh & Co. Kg | Verfahren zur Herstellung reiner Thioctsäure |
US20070299093A1 (en) * | 2005-01-27 | 2007-12-27 | Alma Mater Studiorum-Universitá Di Bologna | Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation |
CA2595994A1 (en) * | 2005-01-27 | 2006-08-03 | Alma Mater Studiorum - Universita' Di Bologna | Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation |
KR20110103987A (ko) * | 2008-12-01 | 2011-09-21 | 인베이스크 테라퓨틱, 인크. | 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도 |
IT1399923B1 (it) * | 2010-05-11 | 2013-05-09 | Cbb Net S A | Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono |
CN105622571A (zh) * | 2016-03-08 | 2016-06-01 | 苏州富士莱医药股份有限公司 | 一种r-硫辛酸氨基丁三醇盐的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3562273A (en) * | 1966-02-17 | 1971-02-09 | Ferrer Labor | Tris (hydroxymethyl) aminomethane theophylline acetate |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT95826B (pt) | 1989-11-09 | 1997-11-28 | Asta Medica Ag | Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico |
DE4037440A1 (de) | 1990-11-24 | 1992-05-27 | Basf Ag | Verfahren zur herstellung von (6s)-6,8-dihydroxyoctansaeureestern |
DE4137773A1 (de) | 1991-11-16 | 1993-05-19 | Degussa | Herstellung und verwendung von salzen der reinen enantiomere der (alpha)-liponsaeure |
DE4235912C2 (de) * | 1992-10-23 | 2002-12-05 | Viatris Gmbh | Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung |
DE4343593C2 (de) * | 1993-12-21 | 1998-05-20 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz |
DE4343592C2 (de) | 1993-12-21 | 1998-04-16 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure und dessen Metaboliten in Form der freien Säure oder als Salze oder Ester oder Amide zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystems |
DE4433764A1 (de) * | 1994-09-22 | 1996-03-28 | Asta Medica Ag | Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit |
DE19533881A1 (de) | 1995-09-13 | 1997-03-20 | Dresden Arzneimittel | Herstellung und Verwendung der reinen Enantiomere der 8-Chlor-6-sulfonyloxy-octansäuren und ihrer Alkylester und der reinen Enantiomere der 6,8-Dichlor-octansäure und ihrer Alkylester |
DE19533882A1 (de) | 1995-09-13 | 1997-03-20 | Dresden Arzneimittel | Herstellung und Verwendung der reinen Enantiomere der 8-Halogen-6-hydroxyoctansäuren, ihrer Alkylester und ihrer Salze mit reinen Enantiomeren des alpha-Methylbenzylamins |
DE19709069C2 (de) | 1997-03-06 | 2000-04-06 | Asta Medica Ag | Enantiomerenreine 3-Hydroxyoctandisäurediester, Verfahren zur Herstellung derselben durch asymmetrische katalytische Hydrierung sowie Verfahren zur Herstellung von R-(+)- und S-(-)-alpha-Liponsäure |
DE19818563C2 (de) | 1998-04-25 | 2003-04-17 | Sueddeutsche Kalkstickstoff | Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung |
DE19834608A1 (de) * | 1998-07-31 | 2000-02-03 | Basf Ag | Kristallmodifikation der Liponsäure |
AR042572A1 (es) * | 1999-04-02 | 2005-06-29 | Sod Conseils Rech Applic | Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos |
AU7995300A (en) * | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
US6387945B2 (en) * | 2000-04-11 | 2002-05-14 | The Regents Of The University Of California | Lipoic acid analogs |
IT1319194B1 (it) * | 2000-10-10 | 2003-09-26 | Laboratorio Chimico Int Spa | Processo per la produzione dell'acido tiottico racemo. |
IT1319195B1 (it) * | 2000-10-10 | 2003-09-26 | Laboratorio Chimico Int Spa | Processo per la produzione dell'acido r(+)alfa-lipoico. |
-
2001
- 2001-07-31 DE DE10137381A patent/DE10137381A1/de not_active Withdrawn
-
2002
- 2002-07-02 CN CNB2006100050932A patent/CN100410248C/zh not_active Expired - Fee Related
- 2002-07-02 EP EP20020743253 patent/EP1417199A1/de not_active Withdrawn
- 2002-07-02 CN CNB02815066XA patent/CN1309718C/zh not_active Expired - Fee Related
- 2002-07-02 CA CA2451979A patent/CA2451979C/en not_active Expired - Fee Related
- 2002-07-02 JP JP2003517044A patent/JP2005506969A/ja active Pending
- 2002-07-02 WO PCT/EP2002/007310 patent/WO2003011852A1/de active Application Filing
- 2002-07-02 KR KR1020047001501A patent/KR100913684B1/ko not_active IP Right Cessation
- 2002-07-30 US US10/207,201 patent/US6844449B2/en not_active Expired - Fee Related
-
2004
- 2004-06-18 US US10/870,157 patent/US7030251B2/en not_active Expired - Fee Related
- 2004-06-30 US US10/879,092 patent/US20050004208A1/en not_active Abandoned
-
2007
- 2007-05-15 HK HK07105123.2A patent/HK1098743A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3562273A (en) * | 1966-02-17 | 1971-02-09 | Ferrer Labor | Tris (hydroxymethyl) aminomethane theophylline acetate |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100935554B1 (ko) | 2009-06-24 | 2010-01-07 | 주식회사 셀트리온제약 | 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물 |
US8541601B2 (en) | 2009-06-24 | 2013-09-24 | Celltrion Chemical Research Institute | Piperazine dithioctate and pharmaceutical composition comprising the same |
CN113197845A (zh) * | 2020-12-16 | 2021-08-03 | 南京海融制药有限公司 | 一种硫辛酸氨丁三醇注射液及其制备方法 |
CN113200959A (zh) * | 2020-12-16 | 2021-08-03 | 南京海融制药有限公司 | 一种硫辛酸氨丁三醇盐晶型及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1417199A1 (de) | 2004-05-12 |
DE10137381A1 (de) | 2003-02-13 |
JP2005506969A (ja) | 2005-03-10 |
CN100410248C (zh) | 2008-08-13 |
US6844449B2 (en) | 2005-01-18 |
CN1537109A (zh) | 2004-10-13 |
US20040225007A1 (en) | 2004-11-11 |
KR20040043171A (ko) | 2004-05-22 |
US7030251B2 (en) | 2006-04-18 |
KR100913684B1 (ko) | 2009-08-24 |
CN1309718C (zh) | 2007-04-11 |
CN1869033A (zh) | 2006-11-29 |
HK1098743A1 (en) | 2007-07-27 |
US20030050332A1 (en) | 2003-03-13 |
CA2451979A1 (en) | 2003-02-13 |
US20050004208A1 (en) | 2005-01-06 |
CA2451979C (en) | 2011-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0096297B1 (de) | Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten | |
DE60105113T2 (de) | Verfahren zur Herstellung von einem Kristallepoxid | |
WO2003011852A1 (de) | Neue modifikationen des trometamolsalzes der r-thioctsäure sowie verfahren zu ihrer herstellung | |
EP0028765A1 (de) | Alkylharnstoffderivate zur Behandlung von Erkrankungen des Fettstoffwechsels; Verfahren zu deren Herstellung, deren Verwendung in Arzneimitteln zur Behandlung von Fettstoffwechselstörungen, diese enthaltende Arzneimittel, Verfahren zur Herstellung der Arzneimittel sowie einige Alkylharnstoffverbindungen | |
DE2112026B2 (de) | 3-Phenyl-H2-[pyrroUdinyl-(l)] äthylamino)-3,4dihydroisochinolin, seiner Herstellung und die es enthaltenden medizinischen Zusammensetzungen | |
DE2628558A1 (de) | Verfahren zur herstellung von lofepraminhydrochlorid | |
EP0622366B1 (de) | Kondensierte Chinolyl-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln zur Behandlung von Herz-Kreislauferkrangen | |
DE60116514T2 (de) | Amlodipinhemimaleat | |
DE2903615A1 (de) | Guajakacylester von mercaptopropionsaeurederivaten, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
WO1979000426A1 (en) | Cyclic diamine n,n'-disubstituted and process for preparing the same | |
DE60011739T2 (de) | Kristallines oder kristallisiertes Säureadditionssalz von Losartan und Verfahren zur Reinigung von Losartan | |
EP1237892B1 (de) | Verfahren zur herstellung von epinastine-hydrochlorid in der hochschmelzenden kristallmodifikation | |
DE3223877C2 (de) | ||
DE2717001A1 (de) | Arzneimittel mit antithrombotischer wirkung | |
DE2927452A1 (de) | Neue derivate des daunorubicins, ihre herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen | |
DE2709109A1 (de) | Verfahren zur herstellung von 1-tert.butylamino-3-(2,5-dichlorphenoxy)-2-propanol einschliesslich seiner enantiomere sowie von saeureadditionssalzen desselben | |
DE2435222C2 (de) | Verfahren zur Herstellung von N-(2-Diethylamino)-ethyl-2-methoxy-5-methylsulfonylbenzamid | |
AT389310B (de) | Cyclohexandion-derivat und verfahren zu seiner herstellung | |
DE69915274T2 (de) | Verfahren zur herstellung von methyl(2s)-2-[(3r)-3-(n-[tert-butyloxycarbonyl -amino -2-oxopyrrolidin-1-yl]propionate | |
DE2521159C2 (de) | Verfahren zur Herstellung von N-(4-Fluorphenyl)-2,3-dichlormaleinsäureimid | |
AT221531B (de) | Verfahren zur Herstellung von neuen Barbitursäure-Verbindungen | |
DE2911492C2 (de) | 5-Substituierte Picolinsäuren, deren Natrium-, Kalium-, Magnesium-, Calcium- und Aluminiumsalze, 5-Indanylester und Säureamide Verfahren zu deren Herstellung und antihypertonische Mittel, welche diese enthalten | |
DE1258416B (de) | Verfahren zur Herstellung von L-alpha-Methyl-beta-(3, 4-dihydroxyphenyl)-alanin | |
AT262991B (de) | Verfahren zur Herstellung von neuen Thienobenzothiazinderivaten | |
CH649526A5 (en) | Process for the preparation of (Z)-1,2-diphenyl-1-[p-(2-dimethyl-aminoethoxy)phenyl]but-1-ene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002743253 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2451979 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003517044 Country of ref document: JP Ref document number: 2002815066X Country of ref document: CN Ref document number: 1020047001501 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2002743253 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |